GlassScriptPhysician profile
Leah M Otto
NPI 1336774520
$1,924.92
in general payments reported to CMS, 2019-2025
15 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,657 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $357.43 | 2023-2025 | Xywav, Epidiolex |
| Abbvie INC. | $268.73 | 2023 | |
| Pfizer INC. | $221.33 | 2023 | |
| Genentech USA, INC. | $212.27 | 2023 | Ocrevus, Enspryng |
| Inspire Medical Systems, INC. | $181.85 | 2023-2025 | Inspire |
| Neurelis, INC. | $172.64 | 2023 | Valtoco |
| Harmony Biosciences LLC | $163.73 | 2023 | Wakix |
| Celgene Corporation | $93.89 | 2023 | Zeposia |
| Acadia Pharmaceuticals INC | $76.76 | 2023 | Nuplazid |
| Merck Sharp & Dohme LLC | $41.08 | 2023 | Belsomra |
| Octapharma USA, INC. | $40.00 | 2023 | Panzyga |
| Ucb, INC. | $39.89 | 2023 | Nayzilam |
| Sk Life Science, INC. | $23.79 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.15 | 2023 | Gammagard |
| Impel Pharmaceuticals INC. | $13.38 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Otto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.